Figure 1Stability of ML355 measured as percent composition of probe molecule in aqueous solution (contains 20 % acetonitrile) at r.t. over the indicated time period in (A) pH 2 buffer , (B) PBS pH 7.4 buffer, (C) 1M HEPES pH 7.3 Lipoxygenase UV-Vis assay buffer, (D) and in the presence of 5 mM glutathione (reduced form)
- PMCPubMed Central citations
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase.[J Med Chem. 2014]Synthesis and structure-activity relationship studies of 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase.Luci DK, Jameson JB 2nd, Yasgar A, Diaz G, Joshi N, Kantz A, Markham K, Perry S, Kuhn N, Yeung J, et al. J Med Chem. 2014 Jan 23; 57(2):495-506. Epub 2014 Jan 6.
- Review Discovery of ML351, a Potent and Selective Inhibitor of Human 15-Lipoxygenase-1.[Probe Reports from the NIH Mol...]Review Discovery of ML351, a Potent and Selective Inhibitor of Human 15-Lipoxygenase-1.Rai G, Joshi N, Perry S, Yasgar A, Schultz L, Jung JE, Liu Y, Terasaki Y, Diaz G, Kenyon V, et al. Probe Reports from the NIH Molecular Libraries Program. 2010
- Fatty acids negatively regulate platelet function through formation of noncanonical 15-lipoxygenase-derived eicosanoids.[Pharmacol Res Perspect. 2023]Fatty acids negatively regulate platelet function through formation of noncanonical 15-lipoxygenase-derived eicosanoids.Yamaguchi A, van Hoorebeke C, Tourdot BE, Perry SC, Lee G, Rhoads N, Rickenberg A, Green AR, Sorrentino J, Yeung J, et al. Pharmacol Res Perspect. 2023 Feb; 11(1):e01056.
- Docking and mutagenesis studies lead to improved inhibitor development of ML355 for human platelet 12-lipoxygenase.[Bioorg Med Chem. 2021]Docking and mutagenesis studies lead to improved inhibitor development of ML355 for human platelet 12-lipoxygenase.Tsai WC, Aleem AM, Tena J, Rivera-Velazquez M, Brah HS, Tripathi S, D'silva M, Nadler JL, Kalyanaraman C, Jacobson MP, et al. Bioorg Med Chem. 2021 Sep 15; 46:116347. Epub 2021 Aug 4.
- Review Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy.[Trends Pharmacol Sci. 2017]Review Targeting 12-Lipoxygenase as a Potential Novel Antiplatelet Therapy.Tourdot BE, Holinstat M. Trends Pharmacol Sci. 2017 Nov; 38(11):1006-1015. Epub 2017 Aug 29.
- Figure 1, Stability of ML355 measured as percent composition of probe molecule i...Figure 1, Stability of ML355 measured as percent composition of probe molecule in aqueous solution (contains 20 % acetonitrile) at r.t. over the indicated time period in (A) pH 2 buffer , (B) PBS pH 7.4 buffer, (C) 1M HEPES pH 7.3 Lipoxygenase UV-Vis assay buffer, (D) and in the presence of 5 mM glutathione (reduced form) - Probe Reports from the NIH Molecular Libraries Program
- Figure 1, Stability of ML351 measured as percent composition of probe molecule i...Figure 1, Stability of ML351 measured as percent composition of probe molecule in aqueous solution (contains 20 % acetonitrile) at room temperature over 48 hr in (A) DPBS pH 7.4 buffer, (b) Lipoxygenase UV-Vis assay buffer of 1M HEPES pH 7.3, (C) pH 2 buffer and (D) pH 10 buffer - Probe Reports from the NIH Molecular Libraries Program
- An inhibitor of the Cdc2-like kinase 4 (Clk4) - Probe Reports from the NIH Molec...An inhibitor of the Cdc2-like kinase 4 (Clk4) - Probe Reports from the NIH Molecular Libraries Program
Your browsing activity is empty.
Activity recording is turned off.
See more...